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Feature Extraction from SIDER
For each potential side effect a vector encoding describing the likelihood of that effect in terms of 5 categories (very rare, rare, uncommon, common, very common) was created. This was done as follows: SIDER provides side effect frequencies for drugs in three different formats:
A) intervals (e. g. 0 to 17%, 0-2%) B) percentages C) frequency categories (e. g. common, rare, ... )
For robustness reasons our aim was to map all side effects to ordinal categories. Obviously cases A) and B) impose a challenge in that context, which we addressed as follows: Intervals (case A) were parsed and mean effect frequencies extracted. We then applied the WHO definition of frequency of adverse drug reactions associated intervals 1 to map these frequencies to one of the defined categories:
Finally we counted for each particular side effect the number of prescriptions within a quarter that could induce a rare, common, etc. effect and generated a corresponding vector, for example: Headache common Headache rare Headache very common 3 1 2
Feature Extraction from DisGeNET
DisGeNET contains about 161,000 confidence scored gene-disease-associations for about 12,400 genes and 1,100 diseases based on various manually curated databases and text-mining derived associations. Since we were only interested in strong disease associations, we took only results into account, which were either manually curated or, if based on text-mining, had a score greater or equal than the smallest confidence score of any manually curated result AND was mentioned in at least 10 publications. This approach resulted into 13,168 associations between 4,512 genes and 537 diseases. 
Feature Extraction from MEDI

Features Derived from EHR Data
Total AED quantity per quarter
The aggregated physiological effect of a particular AED depends on the prescribed quantity (e. g. number of tablets or drops), the route of administration (e. g. oral, sublingual, rectal) and the dose (e.g. 50mg). Claims data from Truven contains for each prescription start and stop dates, day supply and prescribed quantity, which allows to derive the daily drug quantity as the ratio between prescribed quantity and day supply. Hence, for a given drug with defined route of administration and dose it is possible to aggregate the daily quantity to a quarterly quantity. Hence, there was one numeric feature per drug, route of administration, dose and quarter. 
Figure S1: Kaplan Meier curves of focused comorbidities. Event probability as a function of time after index date. First predictions were made 180 days after index date (time 0). The total population consists of incident (at least one incident focused comorbidity after 180) and censored patients (none of the focused comorbidity observed at any time). nCV = number of times that a feature of the corresponding domain / sub-domain was selected during 6-fold cross-validation nCV = number of times that a feature of the corresponding domain / sub-domain was selected during 6-fold cross-validation Table S9 : Hypertension -cumulated importance, stability and overrepresentation of feature domains. 457 features had a positive importance value. nCV = number of times that a feature of the corresponding domain / sub-domain was selected during 6-fold cross-validation Table S10 : Migraine -cumulated importance, stability and overrepresentation of feature domains. 454 features had a positive importance value. nCV = number of times that a feature of the corresponding domain / sub-domain was selected during 6-fold cross-validation Table S18 : Depression -cumulative importance, stability and overrepresentation of selected drug related feature sub-domains nCV = number of times that a feature of the corresponding domain / sub-domain was selected during 6-fold cross-validation Table S19 : Diabetes -cumulative importance, stability and overrepresentation of selected drug related feature sub-domains nCV = number of times that a feature of the corresponding domain / sub-domain was selected during 6-fold cross-validation Table S20 : Hyperlipidemia -cumulative importance, stability and overrepresentation of selected drug related feature sub-domains nCV = number of times that a feature of the corresponding domain / sub-domain was selected during 6-fold cross-validation Table S21 : Hypertension -cumulative importance, stability and overrepresentation of selected drug related feature sub-domains nCV = number of times that a feature of the corresponding domain / sub-domain was selected during 6-fold cross-validation Table S22 : Migraine -cumulative importance, stability and overrepresentation of selected drug related feature sub-domains nCV = number of times that a feature of the corresponding domain / sub-domain was selected during 6-fold cross-validation Table S23 : Overweight -cumulative importance, stability and overrepresentation of selected drug related feature sub-domains nCV = number of times that a feature of the corresponding domain / sub-domain was selected during 6-fold cross-validation 
Variable Importances and Stability
